Anupam Rasayan signs MoU with 3xper Innoventure for new age pharma molecules

The identified products for Active Pharmaceutical Ingredients (API) will be developed under the CRAMS and CDMO models

Granules India successfully completes Two US FDA Audits in a span of 2 weeks

The zero-observation outcome reflects the company's robust quality management systems and commitment to excellence in its operations.

Natural Capsules announces strategic investment by Somerset Indus Capital Partners

Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India

Sajjan India Limited is looking for expansion, both organically and through acquisitions, to achieve the planned growth

Euroapi plans initiatives to support production of APIs in France and Europe

Total investments could reach €70 million, of which approximately 15% in R&D and 85% in capex, that would be deployed from 2026

Ind-Swift Laboratories reports FY23 PAT at Rs. 42.47 Cr

The company reported lifetime high EBIDTA of Rs. 250 crores

Hikal announces USFDA audit with zero observations

This latest audit re-emphasizes Hikal's commitment towards maintaining the best in class quality, compliance and regulatory standards across our manufacturing sites

PI Industries announces twin acquisitions into Pharma API & CDMO space

Neogen Chemicals to acquire 100% stake in BuLi Chemicals India from Livent

This acquisition will boost Neogen's portfolio by offering organolithium derivatives to existing pharma industry

Aarti Drugs Q3 FY23 revenue grows 4%

Standalone Q3 FY23 revenue stood at Rs. 626.5 crore as against Rs. 594.8 crore, a growth of 5% YoY